Today we published our Annual Impact Sheet of 2018.

The Anticancer Fund strongly relies on private funding and donations.

62% of our 2.1 million spending was used on research and clinical trials, our core activity. For CUSP9v3, a brain cancer trial, first results were successfully reported in 2018.

In addition to our 15 supported clinical projects, the Anticancer Fund was also actively involved in cancer policy, as well as in informing patients on cancer treatments. A pilot project on individual patient guidance was set up, My Cancer Navigator.

Read the full report here.